Insulin resistance and lipid disorders

Future Lipidology

Volumn 3, Issue 6, 2008, Pages 651-664

  Miccoli, Roberto ^a   Bianchi, Cristina ^a   Penno, Giuseppe ^a   Del Prato, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Cell failure; Diabetes; Insulin resistance; Triglyceride metabolism

Indexed keywords

ACYL COENZYME A DESATURASE; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; ATORVASTATIN; FATTY ACID; FATTY ACID BINDING PROTEIN; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHOLIPID TRANSFER PROTEIN; PIOGLITAZONE; PLACEBO; RIMONABANT; ROSIGLITAZONE; ROSUVASTATIN; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANTIINFLAMMATORY ACTIVITY; BODY FAT; BODY MASS; CALORIC INTAKE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG MECHANISM; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUSHING; GLUCOSE METABOLISM; HIGH FIBER DIET; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID STORAGE; LIPOLYSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PHYSICAL ACTIVITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SITTING;

EID: 67149086828     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.3.6.651     Document Type: Review

References (128)

1. Farag A, Karam J, Nicasio J, McFarlane SI: Prevention of Type 2 diabetes: an update. Curr. Diab. Rep. 7, 200-207 (2007).
2. Pi-Sunyer FX: How effective are lifestyle changes in the prevention of Type 2 diabetes mellitus? Nutr. Rev. 65, 101-110. (2007).
3. Reaven GM: Pathophysiology of insulin resistance in human disease. Physiol. Rev. 75, 473-486 (1995).
4. Grundy SM: Small LDL, atherogenic dyslipidemia and the metabolic syndrome. Circulation 95 1-4 (1997).
5. Ginsberg HN, Zhang YL, Hernandez-Ono A: Metabolic syndrome: focus on dyslipidemia. Obesity 14(1), 41S-49S (2006).
6. D'Agostino RB Jr, Hamman RF, Karter AJ, Mykkanen L, Wagenknecht LE, Haffner SM; Insulin Resistance Atherosclerosis Study Investigators: Cardiovascular disease risk factors predict the development of Type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes Care 27(9), 2234-2240 (2004).
7. Baldeweg SE, Golay A, Natali A, Balkau B, Del Prato S, Coppack SW: Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans: European Group for the Study of Insulin Resistance (EGIR). Eur. J. Clin. Invest. 30, 45-52 (2000).
8. Festa A, Williams K, Hanley AJ et al.: Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 111 (25), 3465-3472 (2005).
9. Chen YD, Swami S, Skowronski R, Coulston A, Reaven GM: Differences in postprandial lipemia between patients with normal glucose tolerance and non-insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 76, 172-177 (1993).
10. Lewis GF, O'Meara NM, Sokys PA et al.: Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J. Clin. Endocrinol. Metab. 72, 934-944 (1991).
11. Syvänne M, Hilden H, Taskinen MR: Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary artery disease. J. Lipid Res. 35, 15-26 (1994)
12. Cavallero E, Dachet C, Neufcour D, Wirquin E, Mathe D, Jacotot B: Postprandial amplification of lipoprotein abnormalities in controlled Type II diabetic subjects: relationship to postprandial lipemia and C-peptide: glucagon levels. Metabolism 43, 270-278 (1994).
13. Rivellese AA, De Natale C, Di Marino L et al.: Exogenous and endogenous postprandial lipid abnormalities in Type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. J. Clin. Endocrinol. Metab. 89(5), 2153-2159 (2004).
14. Annuzzi G, De Natale C, Iovine C et al.: Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in Type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 24, 2397-2402 (2004).
15. Mero N, Malmström R, Steiner G, Taskinen MR, Syvänne M: Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in Type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis 150, 167-177 (2000).
16. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356-359 (2002).
17. Miccoli R, Bianchi C, Odoguardi L et al.: Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr. Metab. Cardiovasc. Dis. 15(15), 250-254 (2005).
18. Wyszynski DF, Waterworth DM, Barter PJ et al.: Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am. J. Cardiol. 95(2), 194-198 (2005).
19. Rivellese AA, Patti L, Kaufman D et al.: Lipoprotein particle distribution and size, insulin resistance and metabolic syndrome in Alaska Eskimos: the GOCADAN Study. Atherosclerosis (2008).
20. Ghiadoni L, Penno G, Giannarelli C et al.: Metabolic syndrome and vascular alterations in normotensive subjects at risk of diabetes mellitus. Hypertension 51(2), 440-445 (2008).
21. Ginsberg HN, Zhang YL, Hernandez-Ono A: Regulation of plasma triglycerides in insulin resistance and diabetes. Arch. Med. Res. 36, 232-240 (2005).
22. Krauss RM: Triglycerides and atherogenic lipoproteins: rationale for lipid management. Am. J. Med. 105(1A), 58S-62S (1998).
23. Ginsberg HN: Insulin resistance and cardiovascular disease. J. Clin. Invest. 106, 453-458 (2000).
24. Berg CE, Lavan BE, Rondinone CM: Rapamycin partially prevents insulin resistance induced by chronic insulin treatment. Biochem. Biophys. Res. Commun. 293(3), 1021-1027 (2002).
25. Fisher EA, Ginsberg HN: Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J. Biol. Chem. 277, 17377-17380 (2002)
26. Gusarova V, Caplan AJ, Brodsky JL, Fisher EA: Apoprotein B degradation is promoted by the molecular chaperones Hsp90 and Hsp70. J. Biol. Chem. 276, 24891-24900 (2001).
27. Sparks JD, Sparks CE: Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim. Biophys. Acta. 1215, 9-32 (1994).
28. Au WS, Kung HF, Lin MC: Regulation of microsomal triglyceride transfer protein gene by insulin in HeFG2 cells: roles of MAPKerk and MAPKp38. Diabetes 52, 1073-1080 (2003).
29. Phung TL, Roncone A, Jensen KL, Sparks CE, Sparks JD: Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum. J. Biol. Chem. 272, 30693-30702 (1997).
30. Berti L, Mosthaf L, Kroder G et al.: Glucose-induced translocation of protein kinase C isoforms in rat-1 fibroblasts is paralleled by inhibition of the insulin receptor tyrosine kinase. J. Biol. Chem. 269, 3381-3386 (1994).
31. Lewis GF, Uffelman KD, Szeto LW, Steiner G: Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL ApoB production in normal weight and obese individuals. Diabetes 42, 833-842 (1993).
32. Adieis M, Westerbacka J, Soro-Paavonen A et al.: Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetolagia 50(11), 2356-2365 (2007).
33. Adieis M, Olofsson SO, Taskinen MR, Borén J: Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28, 1225-1236 (2008).
34. Riches FM, Watts GF, Naoumova RP et al.: Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int. J. Obes. Relat. Metab. Disord. 22, 414-423 (1998).
35. Craig WY, Nudk R, Cooper AD: Regulation of apoprotein synthesis and secretion in the human hepatoma Hep G2. The effect of exogenous lipoprotein. In Biol. Chem. 263, 13880-13890 (1988).
36. Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer EJ: Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein ApoA-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J. Clin. Invest. 85, 804-811 (1990).
37. Diraison F, Moulin P, Beylot M: Contribution of hepatic de novo lipogenesis and reesterification of plasma nonesterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab. 29, 478-485 (2003).
38. Schwarz JM, Linfoot P, Dare D, Agbajanian K: Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am. J. Clin Nutr. 77, 43-50 (2003).
39. Horton JD, Goldstein JL, Brown MS: SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131 (2002).
40. Richardson MC, Cameron IT, Simonis CD et al.: Insulin and human chorionic gonadotropin cause a shift in the balance of sterol regulatory element-binding protein (SREBP) isoforms toward the SREBP-1c isoform in cultures of human granulosa cells. J. Clin. Endocrinol. Metab. 90(6), 3738-3746 (2005).
41. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL: Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell. 6(1), 77-86 (2000).
42. Brown MS, Goldstein JL: Selective versus total insulin resistance: a pathogenic paradox. Cell. Metab. 7, 95-96 (2008).
43. Cha JY, Repa JJ: The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J. Biol. Chem. 282, 743-751 (2007).
44. Haidari M, Leung N, Mahbub F et al.: Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein. overproduction. J. Biol. Chem. 277, 31646-31655 (2002).
45. Lewis GF: Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster. Endocrinology 146, 247-255 (2005).
46. Cobri JS, Patterson BW, Uffelman KD, Davignon J, Steiner G: Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J. Clin. Endocrinol. Metab. 89, 3949-3955 (2004).
47. Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF: Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol. 26, 1357-1363 (2006).
48. Lewis GF, Rader DJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96, 1221-1232 (2005).
49. Le Goff W, Guerin M, Chapman MJ: Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol. Ther. 101, 17-38 (2004).
50. Borggreve SE, De Vries R, Dullaart RP: Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and Type 2 diabetes mellitus: role of lipolytic enzymes, lecithin: cholesterol acyltransferase and lipid transfer proteins. Eur. J. Clin. Invest. 33, 1051-1069 (2003).
51. Biddinger SB, Hernandez-Ono A, Rask-Madsen C et al.: Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell. Metab. 7, 125-134 (2008).
52. Soedamah-Muthu SS, Chang YF, Otvos J, Evans RW, Orchard TJ: Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes: a prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 46, 674-682 (2003).
53. Kantartzis K, Rittig K, Cegan A et al.: Fatty liver is independently associated with alterations incirculating HDL2 and HDL3 subfractions. Diabetes Care 31, 366-368 (2008).
54. Murao K, Wada Y, Nakamura T et al.: Effects of glucose and insulin on rat apolipoprotein A-I gene expression. J. Biol. Chem. 273, 18959-18965 (1998).
55. Strauss JG, Frank S, Kratky D et al.: Adenovirus mediated rescue of lipoprotein lipase-deficient mice: lipolysis of triglyceride-rich lipoproteins is essential for HDL maturation in mice. J. Biol. Chem. 276, 36083-36090 (2001).
56. Kontush A, Chapman MJ: Why is HDL functionally deficient in Type 2 diabetes? Curr Diab. Rep. 8, 51-59 (2008).
57. de Souza JA, Vindis G, Hansel B et al.: Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis 197, 84-94 (2008).
58. Oppenheimer MJ, Sundquist K, Bierman EL: Down regulation of high-density lipoprotein receptor in human fibroblasts by insulin and IGF-I. Diabetes 38, 117-122 (1989).
59. Wang Y, Oram JF: Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1. J. Biol. Chem. 277, 5692-5697 (2002).
60. Garvey WT, Kwon S, Zheng D et al.: Effects of insulin resistance and Type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance: Diabetes 52, 453-462 (2003).
61. Lund-Katz S, Laplaud S, Phillips M, Chapman MJ: Apolipoprotein B-100 conformation and particle surface change in human LDL subspecies: implications for LDL receptor interaction. Biochemistry 37, 12867-12874 (1998).
62. Krauss RM: Lipids and lipogroteins in patients with Type 2 diabetes. Diabetes Care 27, 1496-1504 (2004).
63. Gazi I, Tsimihodimos V, Filippatos T, Bairaktari E, Tselepis AD, Elisaf M: Concentration and relarive distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol. Education Program criteria. Metabolism 55, 885-891 (2006).
64. Austin MA: Genetics of low-density lipoprotein subclasses. Curr. Opin. Lipidol. 4, 125-132 (1993).
65. Ordovas JM, Cupples LA, Corella D et al.: Association of cholesteryl ester transfer protein-Taq1B polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham Study. Arterioscler. Thromb. Vasc. Biol. 20, 1323-1329 (2000).
66. Laakso M: Gene variants, insulin resistance and dyslipidemia. Curr. Opin. Lipidol. 15, 115-120 (2004).
67. McGarry JD: What if Minkowski had been ageusic? An alternative angle on diabetes. Science 258(5083), 766-770 (1992).
68. Petersen KF, Shulman GI: Etiology of insulin resistance. Am. J. Med. 119(1), S10-S16 (2006).
69. Unger RH: Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44 (8), 863-870 (1995).
70. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH: β-cell lipotoxicity in the pathogenesis of noninsulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-β-cell relationships. Proc. Natl Acad. Sci. USA 91(23), 10878-10882 (1994).
71. Del Prato S, Enzi G, Vigili de Kreutzenberg S et al.: Insulin regulation of glucose and lipid metabolism in massive obesity. Diabetologia. 33(4), 228-236 (1990).
72. Bonora E, Del Prato S, Bonadonna RC et al.: Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women. Diabetes 41(9), 1151-1159 (1992).
73. Greco AV, Mingrone G, Giancaterini A et al.: Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes 51(1), 144-151 (2002).
74. Yki-Järvinen H: Fat in the liver and insulin resistance. Ann. Med. 37(5), 347-356 (2005).
75. Kotronen A, Yki-Järvinen H: Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28, 27-38 (2008).
76. Sass DA, Chang P, Chopra KB: Nonalcoholic fatty liver disease: a clinical review. Dig. Dis. Sci. 50(1), 171-180 (2005).
77. Agarwal N, Sharma BC: Insulin resistance and clinical aspects of nonalcoholic steatohepatitis (NASH). Hepatol. Res. 33, 92-96 (2005).
78. Francis GA, Fayard E, Picard F, Auwerx J: Nuclear receptors and the control of metabolism Annu. Rev. Physiol. 65, 261-311 (2003).
79. Obici S, Feng Z, Arduini A et al.: Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat. Med. 9, 756-761 (2003).
80. Morino K, Petersen KF, Shulman GI: Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55(2), S9-S15 (2006).
81. Mootha VK, Lindgren CM, Eriksson KF et al.: PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately down-regulated in human diabetes. Nat. Genet. 34, 267-273 (2003).
82. Patti ME, Butte AJ, Crunkhorn S et al.: Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc. Natl Acad. Sci. USA 100(14), 8466-8471 (2003).
83. Maassen JA, Romijn JA, Heine RJ: Fatty acid-induced mitochondrial uncoupling in adipocytes as a key protective factor against insulin resistance and β-cell dysfunction: a new concept in the pathogenesis of obesity-associated Type 2 diabetes mellitus. Diabetologia 50, 2036-2041 (2007).
84. Zong H, Ren JM, Young LH et al.: AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc. Natl Acad. Sci. USA 99(25), 15983-15987 (2002).
85. Wu H, Kanatous SB, Thurmond FA et al.: Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. Science 296, 349-352 (2002).
86. Poitout V, Briaud I, Kelpe C, Hagman D: Gluco-lipotoxicity of the pancreatic β-cell. Ann. Endocrinol. 65(1), 37-41(2004).
87. Prentki M, Joly E, El-Assaad W, Roduit R: Malonyl-CoA Signalling lipid partitioning and glucolipotoxicity β-cell adaptation and failure in the etiology of diabetes. Diabetes 51, S405-S413 (2002).
88. Lupi R, Del Guerra S, Marselli L et al.: Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ2 in the modulation of insulin secretion. Am. J. Physiol. Endocrinol. Metab. 286(4), E560-E567 (2004).
89. Heikkinen S, Auwerx J, Argmann CA: PPARγ in human and mouse physiology. Biochim. Biophys. Acta. 1771(8), 999-1013 (2007).
90. Oh J, Hegele RA: HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect. Dis. 7, 787-796 (2007).
91. Chakravarthy MV, Semenkovich CF: The ABCs of β-cell dysfunction in Type 2 diabetes. Nat. Med. 13, 241-242 (2007).
92. Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW: Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic β-cell dysfunction. Diabetes 56, 2328-2338 (2007).
93. Dubé JJ, Amati F, Stefanovic-Racic M, Toledo FG, Sauers SE, Goodpaster BH: Exercise-induced alterations in intramyocellular lipids and insulin resistance: the athlete's paradox revisited. Am. J. Physiol. Endocrinol. Metab. 294, E882-E888 (2008).
94. Lee JS, Pinnamaneni SK, Eo SJ et al.: Saturated, but not n-6 polyunsaturated, fatty acids induce insulin resistance: role of intramuscular accumulation of lipid metabolites. J. Appl. Physiol. 100, 1467-1474 (2006).
95. Riccardi G, Giacco R, Rivellese AA: Dietary fat, insulin sensitivity and the metabolic syndrome. Clin. Nutr. 23(4), 447-456 (2004).
96. Rivellese AA, Maffettone A, Iovine C et al.: Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. Diabetes Care 19(11), 1207-1213 (1996).
97. Gatti E, Noe D, Pazzucconi F et al.: Differential effect of unsaturated oils and butter on blood glucose and insulin response to carbohydrate in normal volunteers. Eur. J. Clin. Nutr. 46, 161-166 (1992).
98. Bessesen DH: The role of carbohydrates in insulin resistance. J. Nutrition 131, 2782S-2786S (2001).
99. Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353(20), 2121-2134 (2005).
100. Stumvoll M, Häring HU, Matthaei S: Metformin. Endocr. Res. 32(1-2), 39-57 (2007).
101. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, Sanchez-Avila F, Montano-Reyes MA, Uribe M. Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review. World J. Gastroenterol. 12(48), 7826-7831 (2006).
102. Yki-Järvinen H: Thiazolidinediones. N. Engl. J. Med. 351(11), 1106-1118 (2004).
103. Lehrke M, Lazar MA: The many faces of PPARγ. Cell 123(6), 993-999 (2005).
104. Khashab M, Chalasani N: Use of insulin sensitizers in NASH. Endocrinol. Metab. Clin. North Am. 36(4), 1067-1087 (2007).
105. Belfort R, Harrison SA, Brown K et al.: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355, 2297-2307 (2006).
106. Del Prato S, Bianchi C, Marchetti P: β-cell function and anti-diabetic pharmacotherapy. Diabetes Metab. Res. Rev. 23(7), 518-527 (2007).
107. Goldberg RB, Kendall DM, Deeg MA et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care 28(7), 1547-1554 (2005).
108. Chiquette E, Ramirez G, DeFronzo R: A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch. Intern. Med. 164, 2097-2104 (2004).
109. Bolen S, Feldman L, Vassy J et al.: Systematic review: comparative effectiveness and safety of oral medications for Type 2 diabetes mellitus. Ann. Intern. Med. 147(6), 386-399 (2007).
110. Tsimihodimos V, Miltiadous G, Daskalopoulou SS, Mikhailidis DP, Elisaf MS: Fenofibrate: metabolic and pleiotropic effects. Curr. Vasc. Pharmacol. 1, 87-98 (2005).
111. Barter PJ, Rye KA: Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler. Thromb. Vasc. Biol. 28, 39-46 (2008).
112. Avogaro A, Miola M, Favaro A et al.: Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in Type 2 diabetic patients. Eur. J. Clin. Invest. 31(7), 603-609 (2001).
113. Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK: Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 28(6), 1419-1424 (2005).
114. Nissen SE, Wolski K, Topol EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. JAMA 294 (20), 2581-2586 (2005).
115. Kastelein JJ: Refocusing on use of cholesteryl ester transfer protein inhibitors. Am. J. Cardiol. 100(11), S47-S52 (2007).
116. Filippatos TD, Gazi IF, Liberopoulos EN et al.: The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 193, 428-437 (2007).
117. Filippatos TD, Liberopoulos EN, Kostapanos M et al.: The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-β1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes. Metab. 10, 476-483 (2008).
118. Kamanna VS, Kashyap ML: Mechanism of action of niacin. Am. J. Cardiol. 101 (8A), 20B-26B (2008).
119. Paolini JF, Mitchel YB, Reyes R et al.: Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am. J. Cardiol. 101(5), 625-630 (2008).
120. Capuzzi DM, Morgan JM, Brusco OA Jr, Intenzo CM: Niacin dosing: relationship to benefits and adverse effects. Curr. Atheroscler. Rep. 2, 64-71 (2000).
121. Grundy SM, Cleeman JI, Merz CN et al.; National Heart, Lung and Blood Institute; the American College of Cardiology Foundation and the American Heart Association: Implications of recent trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227-239 (2004).
122. Deedwania P, Barter P, Carmena R et al.; Treating to New Targets Investigators: Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368, 919-928 (2006).
123. Stalenhoef AF, Ballantyne CM, Sarti C et al.: A comparative study with rosuvastatin in subjects with metabolic syndromes results of the COMETS study. Eur. Heart J. 26, 2664-2672 (2005).
124. Freeman DJ, Norrie J, Satta N et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation, 103, 357-362 (2001).
125. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361, 2005-2016 (2003).
126. Sever PS, Dahlof B, Poulter NR et al.; ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149-1158 (2003).
127. Jones PH: Clinical significance of recent lipid trials on reducing risk in patients with Type 2 diabetes mellitus. Am. J. Cardiol. 99(4A), 133B-140B (2007).
128. Stein EA, Lane M, Laskarzewski P: Comparison of statins in hypertriglyceridemia. Am. J. Cardiol. 81 (Suppl. 4A), 66B-69B (1998).